576 related articles for article (PubMed ID: 19399748)
1. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
5. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
8. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
10. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
[TBL] [Abstract][Full Text] [Related]
12. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
14. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer, osteoporosis and fracture risk.
Allain TJ
Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer.
Sharifi N; Gulley JL; Dahut WL
JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
[TBL] [Abstract][Full Text] [Related]
17. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
